Columbia University Irving Medical Center

Image-Guided Superficial Radiation Therapy Yields Superior 2-Year Recurrence Rates Compared to Mohs Micrographic Surgery, Cancer Journal Reports

Retrieved on: 
Monday, October 2, 2023
Columbia University, Contraindication, Columbia University Irving Medical Center, Cleveland Clinic, SCC, Radiation, Probability, University, Coagulopathy, Doctor of Philosophy, Skin, Anatomy, ASTRO, Mohs surgery, SRT, Skin cancer, Cancer, NMSC, MMS, BCC, Head, National Comprehensive Cancer Network, Toxicity, Research, Radiation therapy, Neck, SCCS, Medical Subject Headings, Dermatology, Incidence, Death, Patient, Treatment, University of South Florida College of Medicine, Carcinoma, American Society for Radiation Oncology, PubMed, European Society for Medical Oncology, Recurrence, Society, Medical imaging, Veterinary medicine, Dentistry, Pharmaceutical industry, Physician, Surgeon

BURR RIDGE, Ill., Oct. 2, 2023 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT, or IGSRT), today announced a newly published study revealing that IGSRT technology is superior to Mohs micrographic surgery (MMS). Image-Guided SRT is the most advanced nonsurgical treatment for common skin cancers. This peer-reviewed study "supports IGSRT as an effective treatment option for individuals with early stage NMSCs (nonmelanoma skin cancers)." The study is the first to directly compare two-year recurrence probabilities of Image-Guided SRT to Mohs.

Key Points: 
  • The study is the first to directly compare two-year recurrence probabilities of Image-Guided SRT to Mohs.
  • The report, entitled, "Image-guided superficial radiation therapy has superior 2-year recurrence probability to Mohs micrographic surgery," appears in the journal Clinical and Translational Radiation Oncology , which is published by the European Society for Radiotherapy & Oncology (ESTRO).
  • Medical Subject Headings were used to search PubMed for reports of 2-year recurrence probability rates of NMSCs treated by MMS.
  • The authors observe that prior to the invention of Mohs surgery, superficial radiation therapy (SRT) was a standard therapy offered by dermatologists for nonmelanoma skin cancer.

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology

Retrieved on: 
Monday, October 2, 2023
Columbia University, Columbia University Irving Medical Center, Male, ASNC, LV, LVH, N-terminal prohormone of brain natriuretic peptide, Cardiac amyloidosis, Serum, Secondary systemic amyloidosis, Echocardiography, IQR, Hypertrophic cardiomyopathy, ID, Assistant, SUV, ICC, ECV, CMP, ATTR, SAN, Map, Cardiology, Amyloidosis, Oregon Health and Science University Center for Women's Health, PET/CT, Genetic testing, Diagnosis, Liver, CMR, HCM, Society, Arnold, Disease, Medical imaging, Medical device, Hospital, Medicine, Patient, Heart

Attralus-Sponsored Test-Retest repeatability study demonstrates excellent repeatability and supports the potential use of AT-01 imaging to monitor disease progression in patients with cardiac amyloidosis.

Key Points: 
  • Attralus-Sponsored Test-Retest repeatability study demonstrates excellent repeatability and supports the potential use of AT-01 imaging to monitor disease progression in patients with cardiac amyloidosis.
  • AT-01 uptake in cardiac amyloidosis shows moderate and statistically significant correlations with traditional measures of cardiac structure and function.
  • These data were included in oral and poster presentations at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) taking place September 29-October 1, 2023, in Toronto, Canada.
  • These findings support the potential use of this novel imaging agent to monitor disease progression in patients with cardiac amyloidosis.

CurePSP Awards Latest Pathway and Pipeline Grants and Urso Student Fellowship Grants Looking to Take Advantage of Recent Neuroscience Breakthroughs

Retrieved on: 
Thursday, September 28, 2023
Molecule, Columbia University, Translation, Mario Negri Institute for Pharmacological Research, Columbia University Irving Medical Center, Database, Pedunculopontine nucleus, University, Cell death, Therapy, Icahn School of Medicine at Mount Sinai, Stanford University, Epidemiology, Incyte, Role, ISR, Progressive supranuclear palsy, Allied Social Science Associations, Rossy, Research, Brain, Mount Sinai, Biomarker, Tauopathy, Neuron, Student, Patient, Pharmacological Research, SUNY, Integrated stress response, Neuroscience, CBD, Mouse, Diagnosis, Cognitive neuroscience, Gene, TIA1, Alzheimer's disease, PSP, Nursing, Medical device, Park So-yeon

NEW YORK, Sept. 28, 2023 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants and Urso Student Fellowships, totaling over $422,000. Recipients of the grants are: Dr. Kurt Farrell, assistant professor at the Icahn School of Medicine at Mount Sinai; Dr. Blas Couto, researcher at the Institute of Translational and Cognitive Neuroscience (INCyT) in Buenos Aires; Dr. Luana Fioriti, head of laboratory at the Mario Negri Institute for Pharmacological Research in Milan, alongside Dr. Carmela Tartaglia, associate professor at the University of Toronto and clinician at the Rossy PSP Centre; and Dr. Joseph B. Rayman, assistant professor of medical sciences at Columbia University Irving Medical Center. Recipients of the Urso Student Fellowship Grants are: Hania Qamar (mentor: Dr. Naomi Visanji), a graduate student at the University of Toronto; Hasnat Nuri (mentor: Dr. Stewart Clark), an undergraduate student at SUNY at Buffalo; and Soyeon Park (mentor: Dr. Jonathan Lin), an undergraduate student at Stanford University. The studies will make progress in identifying biomarkers, studying pathways for therapeutics and creating a new database of patients in Argentina.

Key Points: 
  • NEW YORK, Sept. 28, 2023 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants and Urso Student Fellowships, totaling over $422,000.
  • Recipients of the Urso Student Fellowship Grants are: Hania Qamar (mentor: Dr. Naomi Visanji), a graduate student at the University of Toronto; Hasnat Nuri (mentor: Dr. Stewart Clark), an undergraduate student at SUNY at Buffalo; and Soyeon Park (mentor: Dr. Jonathan Lin), an undergraduate student at Stanford University.
  • The studies will make progress in identifying biomarkers, studying pathways for therapeutics and creating a new database of patients in Argentina.
  • The newest Urso Student Fellowship grants were awarded to students conducting projects that focus on the complex barriers facing research of PSP and CBD.

BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)

Retrieved on: 
Thursday, September 28, 2023
Columbia University, PDAC, Pancreatic cancer, AACR, CXCR4, PRS, Hope, BioLineRx, Immunotherapy, Doctor of Philosophy, ASCO, TEL, MD, Patient, Pancreas, Columbia University Irving Medical Center, TASE, Cancer, Annual general meeting, American Society of Clinical Oncology, Liver, Rare, PD-1, American Association for Cancer Research, Gemcitabine, Partial-response maximum-likelihood, Society, Conference, Pharmaceutical industry

TEL AVIV, Israel, Sept. 28, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced encouraging data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).

Key Points: 
  • The data were published in an online abstract as part of the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts from September 27-30, 2023.
  • The pilot phase of the Phase 2 study enrolled 11 patients with metastatic pancreatic cancer.
  • A poster of the amended clinical trial design was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6 in Chicago, Illinois (see abstract ).
  • Most pancreatic cancer is incurable and unfortunately newer immunotherapy approaches, while beneficial against other solid tumor types, have had limited efficacy in pancreatic cancer due to immunosuppressive pathways.

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer

Retrieved on: 
Tuesday, September 19, 2023
Columbia University, PDAC, AACR, CXCR4, RECIST, Pancreatic cancer, American Association for Cancer Research, Doctor of Philosophy, EDT, ASCO, TEL, American Society of Clinical Oncology, MD, Patient, Pancreas, Columbia University Irving Medical Center, TASE, Annual general meeting, Rare, PD-1, Society, Conference, Safety, Pharmaceutical industry

TEL AVIV, Israel, Sept. 19, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that pilot phase data from an investigator-initiated, open-label, multicenter Phase 2 clinical trial with motixafortide in first-line pancreatic ductal adenocarcinoma (PDAC) will be presented at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts, September 27-30, 2023. The Phase 2 clinical trial is designed to evaluate the company's CXCR4 inhibitor motixafortide in combination with PD-1 inhibitor cemiplimab and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).

Key Points: 
  • The Phase 2 clinical trial is designed to evaluate the company's CXCR4 inhibitor motixafortide in combination with PD-1 inhibitor cemiplimab and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).
  • Sponsored by Columbia University, the single-arm pilot phase of the Phase 2 trial focused on the safety of the drug combination.
  • Earlier this year, following a review of the pilot phase data, the trial was amended to become a randomized study, with planned enrollment increasing from 30 to 102 patients.
  • Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer
    Presenter: Gulam A. Manji, MD, PhD, Columbia University Irving Medical Center/New York Presbyterian, New York, N.Y.

First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology

Retrieved on: 
Thursday, September 14, 2023
Women, Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Consumer, Clinical Trials, Columbia University, Columbia University Irving Medical Center, Internal bleeding, JADA, RBC, Society, ACOG, Obstetrics, PPH, Trial of the century, Obstetrics and gynaecology, Record, Woman, Multimedia, OGN, Hospital, Bleeding, Patient, Hysterectomy, Department of Obstetrics and Gynecology (Massachusetts General Hospital), ICU, American College, SMM, NYSE, Birth control, Gynaecology, Organon

Organon (NYSE: OGN), a global healthcare company focused on improving women’s health, today announced that Obstetrics & Gynecology (“The Green Journal”), the peer-reviewed journal of the American College of Obstetrics and Gynecology (ACOG), published the results of the RUBY study ( NCT04995887 ) which reached its primary effectiveness outcome of successfully treating abnormal postpartum uterine bleeding and postpartum hemorrhage (PPH) with the JADA® System.1 JADA is an intrauterine vacuum-induced hemorrhage control device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.1

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company focused on improving women’s health, today announced that Obstetrics & Gynecology (“The Green Journal”), the peer-reviewed journal of the American College of Obstetrics and Gynecology (ACOG), published the results of the RUBY study ( NCT04995887 ) which reached its primary effectiveness outcome of successfully treating abnormal postpartum uterine bleeding and postpartum hemorrhage (PPH) with the JADA® System.1 JADA is an intrauterine vacuum-induced hemorrhage control device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.1
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230913796173/en/
    “PPH is a potentially life-threatening obstetric emergency that can occur after childbirth and requires timely medical intervention.1,6 Appropriate management of abnormal postpartum uterine bleeding is critical to minimize the potential clinical consequences of PPH7 and its associated severe maternal morbidities, such as the need for blood transfusions, ICU admission or hysterectomy,”1,8,9 said lead author Dena Goffman, M.D., a maternal-fetal medicine subspecialist, and professor and vice chair for quality and patient safety in the Department of Obstetrics and Gynecology at Columbia University Irving Medical Center in New York.
  • “The new study, which included a larger population than the pivotal trial, showed how the device is being used outside of a controlled clinical trial environment.
  • Secondary outcome measures, including time to bleeding control, in-dwelling time, total blood loss and red blood cell transfusions, were also presented.

Muscular Dystrophy Association Announces Research Grants Totaling $8.4 Million

Retrieved on: 
Wednesday, September 13, 2023
Muscular dystrophy, Mir-126, Muscular Dystrophy Association, SMA, SMN, University, Duchenne muscular dystrophy, EDMD, DM, Grant, Doctor of Philosophy, Barrier, DM1, University of Zurich, Johns Hopkins School of Medicine, Columbia University Irving Medical Center, Tel Aviv University, Emery–Dreifuss muscular dystrophy, University of Iowa, Prognosis, Research, Mentorship, Charcot–Marie–Tooth disease, RNA, CMT, Duchenne, Facial muscles, Glycogen storage disease type II, Student, University of Rochester, Neuromuscular disease, DMD, Patient, Regents of the University of Michigan, Diagnosis, Growth, Regent, B cell, Health, MDA, FDA, Mobile app, ALS, Myotonic dystrophy, LGMD, Disease, Pharmaceutical industry, Medical device, Nursing, Exercise

New York, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the awarding of 37 new grants with a total funding commitment of $8.4 million toward neuromuscular disease research.

Key Points: 
  • New York, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the awarding of 37 new grants with a total funding commitment of $8.4 million toward neuromuscular disease research.
  • The newly funded projects aim to advance research discoveries and new therapy development in multiple areas including amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), Duchenne muscular dystrophy (DMD), Emery-Dreifuss muscular dystrophy (EDMD), limb-girdle muscular dystrophy (LGMD), spinal muscular atrophy (SMA), myotonic dystrophy (DM), and many more.
  • “The Muscular Dystrophy Association has consistently been a leader in advancing treatments for people living with muscular dystrophy, ALS and related neuromuscular diseases,” said Donald S. Wood, Ph.D., President and CEO, Muscular Dystrophy Association.
  • Internship recipients and mentors included:
    These are just a few of the many grants the Muscular Dystrophy Association has pledged to support.

Shape Memory Medical Receives FDA IDE Approval to Initiate AAA-SHAPE, a Head-to-Head Trial

Retrieved on: 
Thursday, September 7, 2023
Medical Supplies, Medical Devices, FDA, Health, Other Health, General Health, Area studies, Technique, Columbia University Irving Medical Center, CE, Abdominal aortic aneurysm, University, Beth Israel Deaconess Medical Center, Aneurysm, Expansion, Section, Pivotal trial, Food and Drug Administration, Journal, AAA, PMDA, Patient, Blood, Randomized controlled trial, Mortality, IDE, EVAR, MPH, Memory, Vascular surgery, Food, Safety, Pharmaceutical industry, Medical imaging, EU, MD

Study participants will be randomized 2:1, either to EVAR plus sac management with IMPEDE-FX RapidFill (the treatment arm) or to standard EVAR (the control arm).

Key Points: 
  • Study participants will be randomized 2:1, either to EVAR plus sac management with IMPEDE-FX RapidFill (the treatment arm) or to standard EVAR (the control arm).
  • Key endpoints will compare sac diameter and volume change, endoleak rates, secondary interventions, and mortality through five years.
  • The investigational device, IMPEDE-FX RapidFill, incorporates the novel shape memory polymer, a proprietary, porous, polyurethane scaffold that is crimped for catheter delivery and self-expands upon contact with blood.
  • The AAA-SHAPE Pivotal Trial is preceded by the AAA-SHAPE early feasibility studies which enrolled a combined 35 patients in New Zealand and the Netherlands.

Dr. Brian A. Levine Continues Partnership With Haute MD Network

Retrieved on: 
Tuesday, September 12, 2023
Awards and decorations of the Civil Air Patrol, Partnership, University, Connolly, University Medical Center, Avenue (magazine), Columbia University Irving Medical Center, NYU, University School, The New Yorker, Infertility, Gynaecology, CNN, NBC, American Society for Reproductive Medicine, New Yorker, Alumni, Fertility, Texas Meritorious Service Award, Trustee, Expert, Castle, NewYork-Presbyterian Hospital, Hospital, Reproductive medicine, Society, Weill Cornell Medicine, Birth control, Obstetrics, New York Post, Microsoft Excel

NEW YORK, Sept. 12, 2023 /PRNewswire-PRWeb/ -- Dr. Brian A. Levine is the founding partner and practice director of CCRM New York. He is board-certified in both reproductive endocrinology and infertility and obstetrics and gynecology. Brian Levine, M.D. leads the industry in normalizing open dialogue about infertility— a medical condition affecting 1 in 8 couples— and educates prospective parents on a national level.

Key Points: 
  • Fertility Expert from New York, Dr. Brian A. Levine, continues his partnership with Haute MD Network, now in his third year.
  • NEW YORK, Sept. 12, 2023 /PRNewswire-PRWeb/ -- Dr. Brian A. Levine is the founding partner and practice director of CCRM New York.
  • Brian Levine, M.D.
  • Brian Levine, M.D.

One Mind Announces the 2023 Rising Star Awards Funding Innovative Research in Mental Health

Retrieved on: 
Tuesday, August 15, 2023
Neurology, Health, Mental Health, Columbia University, Columbia University Irving Medical Center, Depression, Oregon Health & Science University, Therapy, Tic disorder, DPI, Schizophrenia, Disability, DSM-IV codes, Rising Star, Deyo, Research, Multimedia, Risk, Suicide, Brain, History, Doctor of Philosophy, Person, Mount Sinai, Vollum Institute, Assistant professor, Neurosurgery, Post-traumatic stress disorder, ACeS, Icahn School of Medicine at Mount Sinai, Eating, Ponce Health Sciences University, Mental health, Psychiatry, Anxiety, Bipolar disorder, Pharmaceutical industry, Nursing, Saunders

One Mind™, a leading mental health non-profit, has announced the three recipients of the 2023 One Mind Rising Star Awards.

Key Points: 
  • One Mind™, a leading mental health non-profit, has announced the three recipients of the 2023 One Mind Rising Star Awards.
  • View the full release here: https://www.businesswire.com/news/home/20230815929713/en/
    The One Mind Rising Star Awards supports early-career investigators in neuroscience, psychiatry, and related disciplines who pursue research to advance the understanding, treatment, and prevention of mental illness.
  • “We are excited to continue transforming the world’s mental health by supporting this new cohort of the 2023 One Mind Rising Stars,” states One Mind President Brandon Staglin.
  • The 2023 Rising Stars will present their research at a special Science & Innovation Symposium organized during the 29th One Mind Music Festival for Brain Health.